Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group

Med Pediatr Oncol. 1994;22(4):258-60. doi: 10.1002/mpo.2950220409.

Abstract

A total of 15 patients with relapsed Wilms' tumor were treated with carboplatin as a single agent. There were six females and nine males, aged between 2 and 9 years (median:5). The treatment consisted of carboplatin given I.V. as a single agent at a dose of 550 mg/m2 over 1 hour every 3 weeks. There were four (26%) complete responses, four (26%) partial responses, one stable disease, and six with progressive disease. In all patients a total of 56 courses were given and the toxicities found were leukopenia and thrombocytopenia. The overall response rate was encouraging and the toxicity was acceptable and reversible.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / secondary
  • Brazil
  • Carboplatin / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Male
  • Remission Induction
  • Wilms Tumor / drug therapy*
  • Wilms Tumor / secondary

Substances

  • Carboplatin